Celgene to collaborate with PTC on advancing drug discovery efforts

Sep 3 2009NewsGuard 100/100 Score

PTC Therapeutics, Inc. (PTC) today announced that Celgene Corporation has exercised its option to collaborate on advancing drug discovery efforts on an oncology target addressed through the application of PTC's GEMS(TM) (Gene Expression Modulation by Small-molecules) technology.

In September 2007, Celgene made a $20 million equity investment in PTC, which included an option for an exclusive research agreement. Under the terms of the research collaboration agreement, PTC will receive substantial milestone payments for achieving certain discovery, development, regulatory and commercial objectives.

"Celgene's decision to exercise the research option is a wonderful endorsement of our GEMS technology. Celgene is widely recognized for developing novel therapies in areas of high unmet medical need and we look forward to working together to advance this project," said Stuart Peltz, Ph.D., president and CEO of PTC Therapeutics.

http://www.ptcbio.com/

Posted in: Pharmaceutical News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

Study uncovers biological drivers of plasma proteins, offering new insights for disease biomarkers and drug discovery
TxGNN improves drug repurposing by predicting treatments for rare diseases with no approved therapies
The Key Role of iPSC-Derived Microglia in Research and Drug Discovery
Insilico Medicine partners with Inimmune to advance immunotherapeutic discovery
Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery
New deep-learning framework identifies non-addictive pain relief options
Ohio State's novel DHODH inhibitor enters first human trials
New technology streamlines drug discovery using single-molecule tracking

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease